Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS13 deficiency?

Summary

About 60% of patients diagnosed with acute thrombotic thrombocytopenic purpura (TTP) display a severe ADAMTS13 deficiency. Recently, Raife et al. concluded from a small case series, that factor V Leiden (FVL) might constitute a risk factor for acute thrombotic microangiopathy (TMA) without severe ADAMTS13 deficiency. Therefore, we determined ADAMTS13 activity and FVL carrier-ship in 256 consecutive patients presenting with various forms of acute TMA, including patients diagnosed with TTP or hemolytic-uremic syndrome (HUS). The overall prevalence of FVL was 8.2% (6.25% among patients diagnosed with TTP, and 9% among those with HUS) concordant with the FVL prevalence reported in Europe. FVL was present in 9.9% of patients with ADAMTS13 activity <10% and in 9.7% of those with normal ADAMTS13 activity (>50%). We conclude that FVL is not more prevalent inTMA patients without as compared to those with severe ADAMTS13 deficiency. The prevalence of FVL carriers in certain HUS subgroups (HUS with ADAMTS13 activity >50%) reaching 12.3% suggests that a contributory role of FVL in the pathogenesis of defined forms of HUS needs further study.

Keywords

ADAMTS13 activity - factor V Leiden - HUS - thromboticmicroangiopathy - TTP

• References

• 1 Allford SL, Hunt BJ, Rose P. et al Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-73.
• 2 Neumann HP, Salzmann M, Bohnert-Iwan B. et al Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 2003; 40: 676-81.
• 3 Noris M, Brioschi S, Caprioli J. et al Familial haemolytic uraemic syndrome and a MCP mutation. Lancet 2003; 362: 1542-7.
• 4 Bianchi V, Robles R, Alberio L. et al Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-3.
• 5 Furlan M, Robles R, Galbusera M. et al Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
• 6 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
• 7 Veyradier A, Obert B, Houllier A. et al Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-72.
• 8 Vesely SK, George JN, Lämmle B. et al ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-8.
• 9 Matsumoto M, Yagi H, Ishizashi H. et al The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004; 41: 68-74.
• 10 Kremer Hovinga JA, Studt JD, Alberio L. et al von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 2004; 41: 75-82.
• 11 Zheng XL, Kaufman RM, Goodnough LT. et al Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-9.
• 12 Peyvandi F, Ferrari S, Lavoretano S. et al von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004; 127: 433-9.
• 13 Raife TJ, Lentz SR, Atkinson BS. et al Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood 2002; 99: 437-42.
• 14 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
• 15 Bertina RM, Koeleman BP, Koster T. et al Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 16 Dahlbäck B. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost 1999; 25: 273-89.
• 17 Redondo M, Watzke HH, Stucki B. et al Coagulation factors II, V, VII, and X, prothrombin gene 20210G->A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 1020-5.
• 18 Rees DC. The population genetics of factor V Leiden (Arg506Gln). Br J Haematol 1996; 95: 579-86.
• 19 Marz W, Seydewitz H, Winkelmann B. et al Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995; 345: 526.
• 20 Pauer HU, Voigt-Tschirschwitz T, Hinney B. et al Analyzes of three common thrombophilic gene mutations in German women with recurrent abortions. Acta Obstet Gynecol Scand 2003; 82: 942-7.
• 21 Desmarais S, de Moerloose P, Reber G. et al Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347: 1374-5.
• 22 Castoldi E, Brugge JM, Nicolaes GA. et al Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004; 103: 4173-9.
• 23 Van Geet C, Proesmans W, Arnout J. et al Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. Kidney Int 1998; 54: 1324-30.
• 24 Chandler WL, Jelacic S, Boster DR. et al Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346: 23-32.
• 25 Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 2003; 127: 834-9.